EMA's PRAC issues new safety information for healthcare professionals

As part of its advice on safety-related aspects to European Medicines Agency committees stemming from its June 7-10 meetings, the Pharmacovigilance Risk Assessment Committee (PRAC) discussed direct healthcare professional communications (DHPCs) containing important information for Neofordex (dexamethasone) and Xalkori (crizotinib).

Xalkori: Vision disorders, including risk of severe visual loss, need for monitoring in pediatric patients

This DHPC informs healthcare professionals of the risk of ocular toxicity, severe visual loss and the need for monitoring in pediatric patients with Xalkori, marketed by US pharma giant Pfizer (NYSE: PFE).